Sheba Medical Center
Ramat Gan, 52621, Israel
NCT Number: NCT00284219
Cigarette smoking is a major public health problem causing significant morbidity and mortality. Yet, smoking cessation therapies are often ineffective at helping smokers break their addiction.
The mesolimbic dopaminergic reward system plays a crucial role in mediating the reinforcing effects of nicotine. Recently, acute high frequency repetitive transcranial magnetic stimulation (rTMS) of frontal brain regions has been shown to efficiently modulate the mesolimbic dopamine systems in both animals and humans. For this reason, we investigated whether 10 high-frequency (10Hz) rTMS treatments over the left dorsolateral prefrontal cortex can help people to withdraw smoking in comparison to placebo rTMS.
Smokers seeking to quit are recruited through newspaper advertisements. Participants were randomized to 10 days of either real or placebo high frequency rTMS.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Ramat Gan, 52621, Israel
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Smoking over 20 Cig a day -
Exclusion criteria
epilepsy, psychiatry history
-
Sham stimulation will be given at the same location as the active, with special sham coil.
Sheba Medical Center
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00302432
Behavior, Health Behavior
Netanya, Israel
View Trial DetailsNCT07737587
Behavior, Pathologic Processes
Iğdır, Turkey (Türkiye)
View Trial DetailsNCT06191419
Behavior, Chemically-Induced Disorders
Lexington, Kentucky, United States
View Trial DetailsNCT04620915
Behavior, Cancer
Eugene, Oregon, United States
View Trial Details